Dr Reddy’s Laboratories share price was trading at ₹1,193.50 at 10:22 AM today. This followed the news of its Q4 results declaration. The company has reported a 21% rise in consolidated net profit for the fourth quarter ended March 31, 2025.
The net profit stood at ₹1,587 crore, compared to ₹1,307 crore in the same quarter last year. Revenue for the quarter rose 20% to ₹8,506 crore, up from ₹7,083 crore in the previous year. For the full year FY25, the company posted a modest 2% increase in net profit at ₹5,655 crore, supported by a strong 17% rise in revenue at ₹32,554 crore.
As per news reports, this growth was driven by new product launches and better performance in the U.S. market. The company has also reported increased revenue from the acquired Nicotine Replacement Therapy (NRT) business. The NRT business added ₹597 crore in Q4 and ₹1,202 crore in FY25 to the overall revenue.
Dr Reddy’s revenues from North America grew 12% in FY25 to ₹14,520 crore. This was mainly due to new product launches and higher volumes in key products, although some price drops affected overall margins.
The company launched 18 new products in the U.S. during FY25 and filed 10 new drug applications with the U.S. FDA. Currently, 76 product filings are awaiting approval.
Revenue from Europe surged 145%, while India and emerging markets each saw a 16% increase.
Dr Reddy’s has been active in forming strategic alliances. It partnered with Shanghai Henlius Biotech for the U.S. and European sale of a cancer drug biosimilar and joined hands with Bio-Thera Solutions for multiple biosimilars across Southeast Asia and Colombia. The company also received regulatory approvals in the U.K. and the U.S. for new biosimilars.
Despite potential U.S. tariffs on pharmaceutical imports, the company has no current plans to shift manufacturing to the U.S.. However, it is open to acquisitions there.
Dr Reddy’s aims to grow further by focusing on new products and partnerships and maintaining strong operations. The company is confident of strengthening its global footprint.
Read more on: PNB Bank Share Price in Focus Post Q4 FY25 Results: Check What’s Announced in Dividend
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: May 12, 2025, 10:57 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
